https://dspace.mm-aist.ac.tz

Life sciences and Bio-engineering

Research Articles [LISBE]

2025-01-01

# Seroprevalence and molecular analysis of yellow fever virus in mosquitoes at Namanga and Mutukula borders in Tanzania

Kakulu, Remidius

Elsevier

https://doi.org/10.1016/j.ijid.2024.107270 Provided with love from The Nelson Mandela African Institution of Science and Technology Contents lists available at ScienceDirect



International Journal of Infectious Diseases



journal homepage: www.elsevier.com/locate/ijid

# Seroprevalence and molecular analysis of yellow fever virus in mosquitoes at Namanga and Mutukula borders in Tanzania

Remidius Kamuhabwa Kakulu<sup>1,2,\*</sup>, Josephine Vitus Kapinga<sup>2</sup>, Sima Rugarabamu<sup>3</sup>, Elison Kemibala<sup>4</sup>, Medard Beyanga<sup>5</sup>, Peter M. Mbelele<sup>6</sup>, Khalid Massa<sup>2</sup>, Esther Gwae Kimaro<sup>1</sup>, Emmanuel Abraham Mpolya<sup>1,7,8,9</sup>

<sup>1</sup> Department of Health and Biomedical Sciences, School of Life Sciences and Bio-Engineering, Nelson Mandela African Institution of Science and Technology (NM-AIST), Arusha, Tanzania

(INM-AIST), Arusna, Tanzania

<sup>3</sup> Department of Microbiology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania

<sup>4</sup> Muheza Vector Control Institute, Tanzania Ministry of Health, Muheza, Tanzania

<sup>5</sup> National Public Health Laboratory, Tanzania Ministry of Health, Dar es Salaam, Tanzania

<sup>6</sup> Kibong'oto Infectious Disease Hospital, Siha, Tanzania

<sup>7</sup> Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Glasgow, United Kingdom

<sup>8</sup> Center for Global Health, Perelman School of Medicine University of Pennsylvania Philadelphia, PA, USA

<sup>9</sup> Institute for Health Metrics and Evaluation, Population Health Building/Hans Rosling Center, Seattle, WA, USA

# ARTICLE INFO

Article history: Received 17 July 2024 Revised 10 October 2024 Accepted 13 October 2024

Keywords: Yellow fever Border Seroprevalence Mosquito Vector Cross border

# ABSTRACT

*Objectives:* Yellow fever (YF) is a major public health concern, particularly in Africa and South America. This study aimed to detect YF in human and mosquito samples to understand transmission dynamics in the Tanzania–Uganda and Tanzania–Kenya cross-border areas.

*Methods:* Blood samples were collected from individuals aged  $\geq 9$  months for serological testing. Mosquitoes were captured and tested for YF virus RNA. Logistic regression models were used to predict seroprevalence and associated risk factors.

*Results*: The overall YF seroprevalence was 12.5%, with higher rates among older individuals (7.0%) and female participants (immunoglobulin [Ig] G 4.4%, IgM 6.0%). Notably, YF virus RNA was detected in three out of 46 pools of 192 mosquitoes. The odds of testing positive for YF IgG were lower among those with primary education compared with college education (AOR = 0.27, CI: 0.08-0.88) and increased with those experiencing muscle pain (AOR = 4.5, CI: 1.08-18.78) while the odds of testing positive to YF IgM increased with being female (AOR = 4.7, CI: 1.5-14.7), traveling to YF endemic areas (AOR = 5.2, CI: 1.35-44.75), exposure to Aedes mosquitoes (AOR = 3.7, CI: 1.27-10.84) and exhibiting bruising (AOR = 13.5, CI: 1.23-145.72)

*Conclusions:* Although Tanzania has not experienced YF outbreaks, evidence of YF exposure at the studied borders highlights the need for strengthening cross-border surveillance, vector control, and vaccination efforts. Further research is needed to evaluate the country's overall YF risks.

© 2024 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

#### Introduction

Yellow fever (YF) is an acute viral illness caused by the YF virus (YFV), a member of the *Flaviviridae* family. It is transmitted through the bites of infected mosquitoes, predominantly the *Aedes aegypti* species [1]. YF poses a significant public health threat

in tropical regions of Africa and South America, characterized by sporadic outbreaks and a potential for large-scale epidemics [2–4]. The disease manifests as a spectrum of symptoms, ranging from mild febrile illness to severe hepatitis and hemorrhagic fever. Severe cases can lead to organ failure and death, making YF a serious concern in affected regions.

Tanzania, located in East Africa, is classified by the World Health Organization (WHO) as having low risk of YF, given the absence of reported YF cases in human or non-human primates [5,6]. The country's diverse ecological and geographical features provide

\* Corresponding author.

E-mail address: kakuluremidius@gmail.com (R.K. Kakulu).

https://doi.org/10.1016/j.ijid.2024.107270

<sup>&</sup>lt;sup>2</sup> Department of Preventive Services, Ministry of Health, Dodoma, Tanzania

<sup>1201-9712/© 2024</sup> The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

a suitable environment for the primary vector of the YF, the *A. ae-gypti* mosquito. Tanzania shares borders with countries that have reported YF outbreaks, including Kenya and Uganda [7,8]. This geographical proximity increases the likelihood of cross-border transmission and necessitates vigilant surveillance and control efforts to mitigate the risk of outbreaks within Tanzania.

Understanding the seroprevalence of YF antibodies in the population and detecting the presence of the YFV in mosquitoes near specific border areas such as Mutukula and Namanga are crucial for assessing the potential for YF transmission in these regions. Seroprevalence studies can reveal the proportion of individuals with previous exposure to the virus, informing vaccination strategies and highlighting vulnerable populations. Meanwhile, virus detection in mosquitoes is instrumental in evaluating the risk of local transmission and guiding vector control initiatives. The WHO emphasizes the need for conducting a national YF risk assessment to estimate the risk of exposure and determine the control measures based on risk status [9,10].

Previous research has shed light on the risk factors associated with YF transmission. Proximity to forests, where the virus circulates among non-human primates and mosquitoes, increases the risk of exposure [11]. Additionally, urbanization and population movements can influence the spread of the disease, as urban areas with high population densities and inadequate sanitation can create optimal conditions for mosquito breeding and disease transmission. Effective control measures and targeted vaccination campaigns are imperative to reduce the burden of YF and prevent outbreaks. Tanzania's approach to addressing YF primarily centers on entry screening, which includes verification of international vaccination certificates for travelers arriving from areas classified by the WHO as YF risk zones or those who have transited through such areas for  $\geq 12$  hours, as well as the implementation of integrated vector management [12]. Furthermore, syndromic screening is being implemented at airports, ports, and borders by checking the body temperatures of international arrivals and observing for signs and symptoms of the disease.

Despite these measures, Tanzania's mobility and connectivity with neighboring countries endemic to YF and experiencing repeated outbreaks highlight the need for a closer examination of alternative successful approaches. Detection of YF in humans and mosquitoes at cross-border areas will enhance existing knowledge and support efforts to strengthen screening or surveillance systems at the Mutukula and Namanga border areas in Tanzania. It will also inform revision of vaccination policies and strategies, including the potential inclusion of YF vaccination among cross-border communities with increased risk of YF.

# Materials and methods

# Study area

This study was conducted at the Mutukula border area of the Kagera Region, situated between Tanzania and Uganda, and the Namanga border of the Arusha Region, located between Tanzania and Kenya. These borders were selected because of their critical geographical locations, high-volume international traffic with YF-endemic neighboring countries, the diverse ecological and climatic conditions, and the implementation of the East African Community Protocol, which allows cross-border communities to interact freely within the perimeter of 10 km on both sides. The recent population projection for the Namanga and Mutukula wards is 38,872 [13]. Geographically, the Mutukula border, being part of the Missenyi District, boasts a diverse landscape, marked by mountain ranges, swampy valley bottoms, and expansive wetlands. The altitude in this region spans from 900 to 1600 m above sea level. Rainfall follows a bimodal pattern, peaking from March to May and

September to December. The vegetation consists of lush forests in certain areas and widespread savannah bushes in others. The local economy relies on subsistence agriculture, mainly banana crops, fishing in Lake Victoria, and livestock keeping. Similarly, the Namanga border, being part of the Longido District, is characterized by a semi-arid climate, with short rains from October to December and long rains from March to May. The district is traversed by the Great Rift Valley, shaping its diverse ecological landscape encompassing forests and water bodies. Altitudes range from 1251 to 2434 m above sea level, contributing to its unique climate and vegetation. Local economic activities primarily revolve around agriculture, tourism, and livestock keeping, integral to the district's socioeconomic fabric. Both the Namanga and Mutukula borders have numerous porous points; thus, some border community members and travelers cross the border without being screened by health authorities.

Specific hamlets were considered during the selection process on the basis of their proximity and the ecology of the area, including forests, water bodies, population density, and the occurrence of mosquito vectors. In this study, the selected hamlets were Kabwoba, Mgambaizi, Chadimba, Kasharu, Kateebe, and Byamtemba in Mutukula, and Buguruni, Mtaa wa saba, Kisongo, Lesoti, Skarda, and Eworendeke in Namanga.

# Study design and population

A cross-sectional study was conducted between June and July 2023, integrating serological and entomological aspects, targeting both health facilities and households in the study area. The inclusion criteria included individuals aged  $\geq 9$  months. Individuals aged <9 months were excluded because of potential maternally derived immunity against YF. Foreigners were also excluded, as their antibodies might reflect exposure in their countries of origin rather than the study area. Moreover, vaccinated individuals were excluded from the study if they provided proof of being vaccinated (valid vaccination certificates).

# Sample size estimation and sampling technique

Given that the prevalence of fevers in the cross-border zones was unknown during the time of the study, a 50% prevalence was assumed to provide the maximum variance in the binomial distribution [14]. A desired absolute precision of 5% and a 95% confidence level were used, yielding a minimum estimated sample size of 384 individuals. After accounting for a 17.2% contingency for non-responses, refusals, or absences, the final sample size was set at 450 participants.

To determine the sample size for each study location from the overall sample of 450, we used probability-proportional-tosize (PPS) sampling. With populations of 26,532 in Mutukula and 12,340 in Namanga [15], the total population was 38,872. Consequently, the sample size for Mutukula was 306, calculated as  $(26,532/38,872) \times 450$ , and for Namanga, it was 144, calculated as  $(12,340/38,872) \times 450$ . The sample was evenly divided (50:50) between households and health facilities [16]. Taking into account an average household size of four people in a study location [15], the exact number of households needed from each hamlet was determined using PPS sampling based on the hamlet sizes obtained from village registers. Systematic sampling was then applied, with the sampling interval calculated by dividing the total number of households in a hamlet by the required sample size. The first household was selected randomly, and subsequent households were selected using the sampling interval. All eligible members aged  $\geq 9$  months who consented were included until the target sample was reached. For health facilities, the required number of patients was determined using PPS sampling based on average monthly patient counts obtained from health facility medical records. All consenting patients who met the recruitment criteria, including being a resident of a study location for  $\geq 1$  year, were included during the study period.

# Data collection

At both health facilities and households, data were collected using a pre-tested semi-structured questionnaire and face-to-face interviews conducted in Kiswahili (the national language). Information gathered included socio-demographic characteristics, duration of stay in the study area, history of residency/travel in other countries, and history of vaccination against YFV. Body temperature was recorded using a digital clinical thermometer. Data quality assessment was conducted throughout the sampling period by examining the data collected on a daily basis. Before data collection, tools were pre-tested and validated. Risk factor–related questions were drawn from the WHO guide on YF risk assessment in endemic countries of 2014 [9].

# Blood sample collection and handling

Whole blood samples of 5 ml were collected through venipuncture from adults and children aged  $\geq$ 10 years, whereas 2-ml whole blood samples were collected from children aged between 9 months and 10 years for serological testing. All procedures for sample collection were performed in accordance with the WHO protocol and the existing standard operating procedure at the Tanzania National Public Health Laboratory. Whole blood samples were transported to the district laboratory for centrifugation. The resulting serum was kept in ice packs during transport to the National Public Health Laboratory of Tanzania, where it was stored at  $-70^{\circ}$ C until examination.

#### Mosquito sample collection and handling

For the entomological investigation, adult and immature stages of mosquitoes were collected in the study area. Adult mosquitoes were trapped using carbon dioxide attractant baits (Biogents AG, Regensburg, Germany) from 6:00 a.m. to 6:00 p.m. outside buildings within 15 m in cool and shaded areas. These mosquitoes were transferred to laboratories at the borders for sorting, identification, recording, and packaging. The sampling procedure used for collecting larvae and pupae is as described by Ngingo et al. [17] and the WHO operational guide for assessing the productivity of A. aegypti mosquito breeding [18]. Forty randomly selected households in each study location were inspected in and around houses for the presence of immature stages. Larvae and pupae were collected from water-holding containers, ditches, puddles, discarded tires, and other potential mosquito breeding habitats using plastic dippers and Pasteur pipettes, and then transferred to labeled water-filled Whirl-Pak plastic bags (Thomas Scientific, Swedesboro, NJ, USA) and transported to the laboratory at the border. The larvae were reared, fed on Whiskas® cat food, and maintained at  $26 \pm 2^{\circ}$ C with  $82 \pm 10\%$  relative humidity. Pupae were transferred to emergence cups in netting cages until adults emerged. The adult mosquitoes were then euthanized at -20°C for 15 minutes and identified morphologically with a stereo-microscope. A total of 543 A. aegypti mosquitoes were collected from all households and pooled into labeled cryovial tubes according to household of origin, and then frozen in liquid nitrogen. These samples were transported in triple packages by a government courier company (Tanzania Posts Corporation) through Express Mail Service (EMS) to the National Public Health Laboratory in Dar es Salaam, Tanzania, for storage and testing.

#### Laboratory procedures

#### Serological testing using ELISA

Human serum samples were tested for immunoglobulin (Ig) G and IgM antibodies against YF using commercial enzyme-linked immunosorbent assay kits (Sunlong Biotech, Co., Ltd, Hangzhou, China), following the manufacturer's instructions. Briefly, 50 µl of serum was dispensed to a 96-well plate pre-coated with the YF virus specific antigen, with samples diluted at a rate of 1:5. Positive and negative controls were included, and one well was left as a blank control. The plate was incubated at 37°C for 30 minutes, washed five times with buffer solution, and then 50 µl of horseradish peroxidase conjugate reagent was added to each well (except the blank). After another 30-minute incubation at 37°C, the plates were washed again five times, and 50 µl of tetramethylbenzidine substrates A and B was added. The plate was gently shaken, covered, and incubated at 37°C for 15 minutes, avoiding light exposure. The horseradish peroxidase catalyzed tetramethylbenzidine to produce a blue color, which turned yellow after adding the acidic stop solution. The intensity of the yellow color was proportional to the amount of YFV-IgM/IgG bound to the plate. The optical density absorbance was measured spectrophotometrically at 450 nm in a microplate reader. The presence of YFV IgM/IgG was determined on the basis of cutoff values established per the manufacturer's guidelines, with effectiveness criteria met when both intra-assay and inter-assay coefficients of variability were <15%.

# Detection of YFV RNA in mosquitoes

Out of 543 adult A. aegypti mosquitoes collected through several techniques, 192 were female and analyzed for YFV. In this case, 46 female A. aegypti mosquito pools, containing 192 mosquitoes (1-4 per pool), were processed for YFV identification using reverse transcription-polymerase chain reaction (RT-PCR). Each homogeneous pool, in terms of collection method, sites, date, and time, was homogenized, vortexed, and centrifuged at 13,000 rpm for 5 minutes to remove tissue debris. The supernatant was collected for RNA extraction using the QIAamp Viral RNA Kit (Qiagen, Hilden, Germany), with RNA eluted in 60 µl of elution buffer, aliquoted into three 20-µl portions, and stored at -80°C. The onestep RT-PCR was performed using RealStar Yellow Fever Virus RT-PCR Kits 1.0 (altona Diagnostics, Hamburg, Germany) in accordance with the manufacturer's instructions on a Bio-Rad CFX96 thermocycler (Bio-Rad Laboratories, Inc., Hercules, CA). The reaction mixture contained 20 µl of the prepared mix and 10 µl of RNA template. The RT-PCR process included reverse transcription at 55°C for 20 minutes, initial denaturation at 95°C for 2 minutes, followed by 45 cycles of denaturation at 95°C for 15 seconds, annealing at 55°C for 45 seconds, and elongation at 72°C for 15 seconds. Successful runs showed a sigmoid curve in the HEX channel for the negative control and in the FAM channel (and possibly HEX channel) for the positive control. YFV-specific RNA detection was confirmed by a sigmoid curve in the FAM channel of the tested sample.

#### Data analysis

Data were captured using a standard questionnaire, cleaned at point of collection, and recorded into the KoboToolbox database for safe storage before statistical analysis. The data were extracted into Excel software and exported to Epi Info software (Centers for Disease Control and Prevention, Atlanta, GA) for analysis. Continuous variables, such as age and body temperature, were expressed as median and interquartile range. The dichotomous variable was analyzed using the chi-square test, and logistic regression was conducted to predict risk factors for YF and control for confounding variables. The level of significance was set at *P*-value <0.05.

Socio-demographic and clinica	l characteristics of	f study par	ticipants by	border.
-------------------------------	----------------------	-------------	--------------	---------

Characteristics	Total	Mutukula border		Namanga border	
Sav	N - 450	Frequency	%	Frequency	%
Male	172	130	28.89	42	933
Female	278	102	20.05	176	39.11
Age (years)	N - 450	102	22.07	170	55.11
0_15	70	54	12.00	16	3 56
16-30	175	118	26.22	57	12 67
31-45	133	80	10.72	11	0.78
46-60	57	38	8 44	19	4 22
>61	15	8	1 78	7	1.56
	N - 450	0	1.70	,	1.50
None	59	32	7 1 1	27	6.00
Primary	289	22	49.78	65	14 44
Secondary	79	42	933	37	8 22
College	75	7	1.56	17	3 78
Main occupation	N = 450	,	1.50	17	5.70
Fmploved	109	79	17 56	59	13 11
Business	22	7	1 56	15	2 22
Cron farming	161	, 151	33 56	10	2.22
Livestock	38	3	0.67	35	7 78
Students	68	50	11 11	18	4 00
Others	24	15	2 22	9	2.00
Vellow fever vaccination status	N = 450	15	5.55	5	2.00
Vaccinated	6	0	0	6	1 33
Not vaccinated	444	306	68 92	138	31.08
Clinical characteristics	N - 450	500	00.02	150	51.00
Bleeding	10	7	15	3	07
Body malaise	30	24	5.4	6	13
Body rashes	20	14	3.1	6	1.3
Bruising	5	5	11	0	0
Reported fever	152	123	27.3	29	65
Headache	84	58	2.9	26	5.8
Muscle pain	46	35	7.8	11	2.4
Nausea	22	20	45	2	0.4
Red eves	10	5	11	5	11
Stomachache	34	24	5.4	10	2.2
Vomiting	19	18	4.0	1	0.2
Jaundice	8	6	1.4	2	0.4
Body temperature	-	-		-	
<37.4°C	361	248	68.7	113	11.5
37.5°C-38.0°C	65	47	10.4	18	4.0
>38°C	16	7	1.6	9	2.0

# Ethical considerations

The study objectives, benefits, and risks were explained in Kiswahili (the national language) to all participants before inclusion. Written informed consent was sought and obtained from all adult participants and parents or legal guardians of children. Furthermore, assent was obtained from participants aged <18 years. Heads of houses were asked for consent and permission before setting the traps in their premises. This study received ethical approval from the Tanzania Medical Research Coordinating Committee of the National Institute for Medical Research (NIMR/HQ/R.8a/Vol IX/4325).

# Results

#### Socio-demographic characteristics

A total of 450 participants took part in the study, with 306 (68%) from Mutukula and 144 (32%) from Namanga, achieving a 100% participation rate. Most participants were female (278, 61.78%), with a mean age of 30 years (SD  $\pm$  16.9). Most participants were aged between 16 and 30 years (175, 38.89%), followed by those aged  $\geq$ 31 years (133, 29.56%). Most had primary education (289, 64.22%), while 59 participants (13.11%) had no formal education, 79 (17.56%) had completed secondary education, and 24 (5.33%) had attended post-secondary education (college). Crop farming was the predominant occupation (161, 33.56%), followed

by formal employment (109, 30.67%). Livestock keeping was more common in Namanga (35, 7.78%) than in Mutukula (3, 0.67%). The median temperature of participants was  $36.9^{\circ}$ C (interquartile range 0.4), with 18% having a temperature >37.5°C. Fever was the most reported symptom (152, 33.8%), followed by headache (84, 18.7%), muscle pain (46, 10.2%), stomachache (34, 7.6%), and body malaise (30, 6.7%). Other symptoms included bleeding, rashes, red eyes, vomiting, and jaundice (Table 1).

# Serological testing

Table 2 summarizes the seroprevalence of IgG and IgM antibodies against YF by socio-demographic characteristics, study area, and sampling location. Overall, the YF antibodies (IgG and IgM) were present in 56 (12.5%) of 450 study participants. The prevalence varied among age groups, with higher rates observed among older individuals aged between 16 and 45 years (9.7%). Notably, female participants exhibited higher seroprevalence than male participants for both IgG (4.4%) and IgM (6.0%) antibodies. Participants with primary education had significantly higher seroprevalence (7.2%) compared with those with no formal education (2.6%), secondary education (1.3%), and college education (1.4%) (P < 0.001). Seroprevalence was higher at the Mutukula border (8.3%) than the Namanga border (4.2%). Regarding sampling location, house-holds exhibited a higher seroprevalence (6.6%) than health facilities (5.9%) (Table 2).

Seroprevalence of IgG and IgM antibodies against YF by socio-demographic characteristics, study area, and sampling location.

Variable		YF		Overall (%)	
		IgG, $P = 5.7$ (%)	IgM, $P = 6.8$ (%)	(IgG + IgM)	
Age (years)	0-15	0.6	0.2	0.8	
	16-30	1.5	2.8	4.3	
	31-45	2.7	2.7	5.4	
	46-60	0.7	0.9	1.6	
	≥60	0.2	0.2	0.4	
Sex	Female	4.4	6.0	10.4	
	Male	1.3	0.8	2.1	
Education level	None	1.1	1.5	2.6	
	Primary	3.5	3.7	7.2	
	Secondary	0	1.3	1.3	
	College	1.1	0.3	1.4	
Borders	Mutukula	3.5	4.8	8.3	
	Namanga	2.2	2.0	4.2	
Sampling location	Household	3.3	3.3	6.6	
	Facility	2.4	3.5	5.9	
Vaccination	Vaccinated	0	0	0	
for YF	Not vaccinated	5.5	7.0	12.5	

Ig, immunoglobulin; YF, yellow fever.

#### Table 3

Prevalence of clinical characteristics by YF status (IgM+IgG).

Clinical characteristics		YF status (IgM + IgG)		
		YF-positive	YF-negative	Chi-squared P-value
Stomachache	Yes No	8 (9.1%) 80 (90.9%)	26 (7.3%) 329(92.7%)	0.111
Headache	Yes No	18 (20.2%) 71 (79.8%)	64 (17.8) 295 (82.2%)	0.137
Body rashes	Yes No	6 (6.7%) 83 (93.3%)	14 (3.9%) 343 (96.1%)	0.746
Bleeding	Yes No	3 (3.4%) 86 (96.6%)	7 (2.0%) 352 (98.0%)	0.169
Body malaise	Yes No	6 (6.8%) 82 (93.2%)	24 (6.7%) 332 (93.3%)	<b>0.000</b> <sup>a</sup>
Bruising	Yes No	4 (4.6%) 84 (95.4%)	1 (0.28%) 355 (99.7%)	<b>0.005</b> <sup>a</sup>
Fever	Yes No	33 (37.1%) 56 (62.9%0	119 (33%) 242 (67%)	0.372
Muscle pain	Yes No	9 (10.2%) 79 (89.8%)	37 (10.3%) 322 (89.7%)	<b>0.000</b> <sup>a</sup>
Nausea	Yes No	4 (4.5%) 85 (95.5%)	18 (5.0%) 340 (95.0%)	<b>0.000</b> <sup>a</sup>
Red eyes	Yes No	2 (2.3%) 86 (97.7%)	8 (2.3%) 348 (97.8%)	<b>0.000</b> <sup>a</sup>
Vomiting	Yes No	3 (3.4%) 86 (96.6%)	16 (4.5%) 340 (95.5%)	<b>0.030</b> ª
Jaundice	Yes No	2 (2.3%) 86 (97.7%)	6 (1.7%) 348 (98.3%)	<b>0.000</b> ª

Ig, immunoglobulin; YF, yellow fever.

<sup>a</sup> P<0.05.

Cross-tabulation of clinical characteristics by YF serostatus (IgM + IgG)

Multivariate analysis of YF seropositivity by socio-demographic, clinical, and exposure risk factors

Table 3 summarizes the analysis of the clinical characteristics by IgM and IgG serostatus. Symptoms such as body malaise, bruising, muscle pain, nausea, red eyes, vomiting, and jaundice were significantly associated with the serological status for YF (P < 0.05).

YF seropositivity increased with age, peaking in the 45- to 60year age group for IgM (adjusted odds ratio [AOR] = 7.76; confidence interval [CI] = 0.8-75.5), although the result was not statistically significant. Participants without formal education were three

Multivariate logistic regression model to predict yellow fever seropositivity (IgG and IgM) by socio-demographic and clinical characteristics.

Predictor	Levels	Dependent variable (IgM)				Dependent variable (IgG)				
variables		AOR	Lower 95% CI%	Upper 95% CI	P-value	AOR	Lower 95% CI	Upper 95% CI	P-value	
Age group	Ref = (0 - 15)  years									
	(15 - 30)	4.83	0.60	39.27	0.14	0.94	0.22	3.94	0.93	
	(30 - 45)	5.98	0.75	47.86	0.09	1.58	0.41	6.06	0.51	
	(45 - 60)	7.76	0.80	75.54	0.08	1.43	0.26	7.74	0.68	
	>60	7.29	0.40	134.00	0.18	1.96	0.18	21.56	0.58	
Sex	Ref = Male									
	Female	4.69	1.49	14.71	0.01 <sup>a</sup>	2.36	0.86	6.46	0.09	
Education	Ref = College									
	None	3.22	0.36	29.03	0.30	0.33	0.08	1.38	0.13	
	Primary	1.96	0.24	15.93	0.53	0.27	0.08	0.88	0.03 <sup>a</sup>	
	Secondary	2.20	0.24	19.99	0.48	0.00	0.00	>1.0E12	0.97	
Occupation	Ref = Business									
	Farmer	191252.38	0.00	>1.0E12	0.96	2342013.31	0.00	>1.0E12	0.98	
	Livestock	235872.83	0.00	>1.0E12	0.96	3728344.02	0.00	>1.0E12	0.98	
	Other	177811.48	0.00	>1.0E12	0.96	3271429.73	0.00	>1.0E12	0.98	
Body	Ref = 37.4									
temperature	37.5-38	0.62	0.18	2.13	0.45	0.22	0.03	1.64	0.14	
(°C)	>38	0.00	0.00	>1.0E12	0.97	0.84	0.10	6.75	0.87	
Clinical signs	Ref = None									
	Bleeding	0.58	0.02	15.38	0.74	0.94	0.06	15.19	0.96	
	Body malaise	0.41	0.04	4.20	0.45	0.09	0.01	1.56	0.10	
	Body rashes	2.75	0.48	15.74	0.26	1.08	0.15	7.89	0.94	
	Bruising	13.51	1.23	148.72	0.03 <sup>a</sup>	4.61	0.29	73.37	0.28	
	Headache	1.14	0.36	3.63	0.83	1.26	0.39	4.05	0.70	
	Muscle pain	1.15	0.20	6.68	0.88	4.51	1.08	18.78	0.04 <sup>a</sup>	
	Nausea	0.00	0.00	>1.0E12	0.97	0.00	0.00	>1.0E12	0.96	
	Red eyes	2.33	0.28	19.51	0.43	5.09	0.74	35.09	0.10	
	Stomachache	2.11	0.64	6.93	0.22	2.16	0.63	7.33	0.22	
	Jaundice	1.44	0.15	13.97	0.76	1.80	0.17	19.11	0.62	
	Vomiting	0.00	0.00	>1.0E12	0.97	0.00	0.00	>1.0E12	0.98	

AOR, adjusted odds ratio; CI, confidence interval; Ig, immunoglobulin; Ref, reference. <sup>a</sup> P<0.05.

times more likely to be IgM-positive for YF compared with those with post-secondary (college) education, but this finding was not statistically significant. Similarly, participants with primary education had significantly lower odds of testing positive for IgG antibodies against YF (AOR = 0.27; CI = 0.08-0.88) compared with those with post-secondary (college) education. Female participants had significantly higher odds of IgM seropositivity than male participants (AOR = 4.7; CI = 1.5-14.7). Symptoms such as muscle pain (AOR = 4.5; CI = 1.08-18.78) and bruising (AOR = 13.5; CI = 1.23-148.72) were significantly associated with seropositivity (Table 4). Regarding risk factors, travel to YF risk areas (AOR = 5.2; CI = 1.35-44.75) and presence of A. aegypti mosquitoes within the household environment (AOR = 3.7: CI = 1.27-10.84) increased IgM seropositivity. Living at the border for >10 years without travel history to YF-endemic areas reduced IgG seropositivity (AOR = 0.2; CI = 0.07 - 0.70) (Table 5).

# Detection of YF virus in mosquitoes

A total of 192 female *A. aegypti* mosquitoes, including both adult and larval stages, were captured and grouped into 46 pools. Remarkably, YFV was detected in three pools (specifically, pools 1, 8, and 43). Among these, two pools comprised adult mosquitoes, while one pool from the larval breeding sites also tested positive for the YFV (Figure 1).

# Discussion

YF remains a public health concern with risk of international spread, posing a potential threat to global health security. This study aimed to detect YF in humans and mosquitoes at Tanzanian border areas connected to YF-endemic countries. The seroprevalence of YF (12.5%) was higher than that observed in 2021 by Rugarabamu et al. (1.4%) [16], who collected samples in different ecological zones throughout the country. The odds of YF seropositivity were significantly (fivefold) higher among participants with a history of travel to YF-endemic neighboring countries compared with those without such history. This finding underscores the role of cross-border mobility and connectivity in shaping transmission dynamics across border areas and highlights potential risk factors [19]. Additionally, notable discrepancies were observed between this study's findings and those from other regions with varying environmental and population profiles, reinforcing the need for context-specific prevention and control strategies [20]. This emphasizes the importance of tailoring interventions on the basis of the country's unique characteristics, including vector populations, climate conditions, and patterns of international travel and crossborder mobility.

The gender-based disparity in YF seroprevalence, with female participants showing a higher rate, is a significant finding. This aligns with similar gender-based variations observed in tropical regions for YF and other flaviviruses [21]. The reasons behind this disparity could be multifaceted, including differences in exposure due to behavioral factors, variations in immunity, or hormonal influences on the immune response [22]. Addressing this gender difference in vulnerability to YF is crucial for designing targeted prevention strategies.

Education level emerged as a significant determinant of YF seroprevalence, with existing research indicating that higher education is typically associated with better health outcomes and lower disease prevalence [23]. Interestingly, while individuals with primary education exhibited higher seroprevalence rates of YF antibodies, they also had lower odds of testing IgG-positive for the virus compared with those with post-secondary (college) education. This might be due to cross-border interactions for schooling purposes in the neighboring YF-endemic countries. This finding aligns with the results of this study, which found that par-

Multivariate logistic regression to predict yellow fever seropositivity status by exposure risk factors.

	Levels	Dependent variable (IgM)				Dependent variable (IgG)			
Predictor variables		AOR	Lower 95 Cl%	Upper 95% CI	P-value	AOR	Lower 95% CI	Upper 95% CI	P-value
History of travel to endemic areas	Ref = No								
	Yes	5.15	1.35	44.75	0.03 <sup>a</sup>	1.96	0.56	6.85	0.29
Presence of Aedes aegypti mosquitoes	Ref =No								
at place of stay	Yes	3.71	1.27	10.84	0.02 <sup>a</sup>	1.59	0.61	4.13	0.34
Reported use of mosquito repellent	Ref = No								
	Yes	0.78	0.30	2.02	0.60	1.33	0.52	3.40	0.55
History of being vaccinated against	Ref = No								
yellow fever	Yes	0.00	0.00	>1.0E12	0.98	0.00	0.00	>1.0E12	0.97
History of frequent visits to forests	Ref = No								
	Yes	1.04	0.33	3.31	0.95	2.09	0.72	6.05	0.17
Reported use of mosquito nets	Ref = No								
	Yes	0.59	0.26	1.33	0.20	0.61	0.26	1.46	0.27
Duration of stay (years) at the border	Ref = ≤1 year								
	>1-6	1.12	0.29	4.33	0.87	0.41	0.11	1.56	0.19
	>6-10	1.61	0.40	6.45	0.50	0.28	0.06	1.33	0.11
	>10	0.43	0.12	1.52	0.19	0.22	0.07	0.70	0.01 <sup>a</sup>
Location where sample was collected	Ref = Household	d							
	Health facility	0.65	0.28	1.48	0.31	0.45	0.18	1.15	0.09

AOR, adjusted odds ratio; CI, confidence interval; Ig, immunoglobulin; Ref, reference.



Figure 1. Amplification and curves of reverse transcription-polymerase chain reaction for yellow fever detection in mosquitoes. NC, negative control; PC, positive control; P1, adult mosquito pool 1; P8, adult mosquito pool 8; P43, Mosquito Larvae Pool 43; RFU, Relative fluorescence unit

ticipants with a history of travel to YF-endemic countries had five times higher odds of being YF seropositive compared with those without such history. This finding challenges the conventional assumption that higher education invariably correlates with improved health outcomes and reduced disease prevalence. It necessitates targeted health education and awareness campaigns for all individuals, specifically addressing the unique needs of those with lower education levels. Moreover, the seroprevalence patterns observed among individuals with primary education are similar to those observed in studies on dengue fever [24], reinforcing the need for targeted health initiatives to improve preventive practices across all educational groups.

Notably, the presence of mosquitoes in surroundings and a history of travel to YF-endemic countries significantly increased the odds of YF IgM seropositivity in our study, consistent with findings from other studies linking YF to international travel and crossborder mobility [23–25]. Detecting YFV in mosquitoes highlights the critical role of vector control in minimizing the risk of YF transmission [26]. These findings reinforce the importance of targeted mosquito control strategies, guided by continuous surveillance to curb YF transmission.

Tanzania's lack of reported YF outbreaks, alongside the reported presence of IgM-positive cases, YFV in mosquitoes, and significantly higher odds of some YF-related symptoms (muscle pain, bruising, vomiting, red eyes, nausea, body malaise, and jaundice), raises concerns about potential undetected or silent transmission, especially in cross-border areas. This highlights the challenges in YF detection due to symptom similarities with other febrile illnesses and the absence of specific diagnostic tests [27]. It underscores the need for comprehensive multi-pathogen cross-border surveillance, robust diagnostic capabilities, and further research to understand the dynamics of YF transmission in the region.

The higher seroprevalence in Mutukula compared with Namanga may be attributed to various factors, including geographical location, proximity, and connectivity to Uganda, a country with frequent reports of YF epidemics [28]. The possibility of cross-border transmission highlights the need for coordinated efforts and collaboration between neighboring countries to effectively control and prevent YF [29]. This suggests that YF control efforts in border regions should be tailored.

This study acknowledges certain limitations, including the ability of study participants to recall mosquito exposure and travel frequency to YF-endemic areas. However, this study provides valuable insights into the prevalence and potential transmission dynamics of YF in cross-border areas. The presence of YF antibodies and YFV in mosquitoes, despite the absence of reported outbreaks, highlights the necessity for robust surveillance and diagnostic capabilities, with the main focus on border areas. The gender disparity in seroprevalence and the higher prevalence in specific border regions underscore the necessity for targeted interventions. International travel to YF-endemic countries and mosquito abundance emerged as potential risk factors, emphasizing the need to implement vector control programs consistent with international health regulations and to enhance health screening at points of entry.

# Conclusion and generalizability

This study highlights the presence of YF antibodies in humans and virus circulation in mosquitoes, indicating a potential risk of undetected transmission in the cross-border buffer zones of Mutukula and Namanga in Tanzania. Presence of mosquito vectors and history of travel to endemic countries emerged as potential risk factors for YF transmission. Gender disparities in seroprevalence and variations in educational levels indicate the need for targeted awareness campaigns. Strengthening effective YF prevention and control strategies, cross-border collaboration, and ongoing research in other regions at risk are highly recommended. These results, although not generalizable to the entire country, highlight the need for a comprehensive national YF risk assessment, as recommended by WHO. The results of this study should guide targeted interventions, including the possible introduction of YF vaccination as part of routine immunization, especially in areas with elevated YF risk.

#### **Declarations of competing interest**

The authors have no competing interests to declare.

# Funding

This study was funded by the Tanzania Ministry of Health, through cooperative agreement with the United States Agency for International Development's Global Health Security project fund.

# **Ethics approval**

Ethical approval was provided by the National Institute for Medical Research Committee.

# Acknowledgments

We express our sincere thanks to the Ministry of Health staff, the National Public Health Laboratory, the Muheza Institute of Vector Control, and the regional and district administrative authorities for allowing and supervising this research work. More specifically, sincere gratitude is extended to Josephine Kapinga (logistics coordinator), Dr. Amour Seleman (Head of port health services), Athanas Lucas, and Nisalile Mwangoka from the Ministry of Health Headquarters; Francis Moreen and Raphael Mwakasege (Global Health Security Agenda), Ambele Mwafulango (Manager), and Ferdinand Ndunguru from the National Public Health Laboratory; and Dr. Kaniki Issessanda (Regional Medical Officer-Kagera region), Vones Uiso (Regional Health Officer-Arusha region), Dr. Daniel Chochole (District Medical Officer-Misenyi District), and Remmy Kibiki and Gabriel Mdachi Port Health Officers in charge at Namanga and Mutukula borders.

# Author contributions

R.K. drafted the manuscript. R.K., J.K., S.R., P.M.M., K.M., E.G.K., and E.M. jointly reviewed and updated the draft manuscript. All authors checked and approved the final report.

#### Availability of data and materials

The data sets used and analyzed during the current study are available from the corresponding author on reasonable request.

#### References

- [1] Silva NIO, Sacchetto L, de Rezende IM, GdS Trindade, LaBeaud AD, de Thoisy B, et al. Recent sylvatic yellow fever virus transmission in Brazil: the news from an old disease. *Virol J* 2020;**17**:9. doi:10.1186/s12985-019-1277-7.
- [2] Carter HR. Yellow fever an epidemiological and historical study of its place of origin. Baltimore: The Williams & Wilkins Company; 1931.
- [3] Barrett ADT, Monath TP. Epidemiology and ecology of yellow fever virus. In: Adv Virus Res. Amsterdam: Elsevier Academic Press; 2003. p. 525.
- [4] Gardner CL, Ryman KD. Yellow fever: a reemerging threat. Clin Lab Med 2010;30:237–60. doi:10.1016/j.cll.2010.01.001.
- [5] World Health Organization (WHO). International travel and health, 18 November 2022 (revised on 3 January 2023), https://cdn.who.int/ media/docs/default-source/travel-and-health/vaccination-requirements-andwho-recommendations-ith-2022-country-list.pdf; 2022 [accessed 10 January 2023].

- [6] Jentes ES, Poumerol G, Gershman MD, Hill DR, Lemarchand J, Lewis RF, et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. *Lancet Infect Dis* 2011;11:622–32. doi:10.1016/S1473-3099(11) 70147-5.
- [7] Ministry of Health. Kenya on alert as it reports outbreak of yellow fever, https://travelhealthpro.org.uk/news/620/yellow-fever-outbreak-in-kenya; 2022 [accessed 10 August 2022].
- [8] World Health Organization. Yellow fever–Uganda, https://www.who.int/ emergencies/disease-outbreak-news/item/2022-DON367; 2022 [accessed 15 April 2022].
- [9] World Health Organization. Risk assessment on yellow fever virus circulation in endemic countries: working document from an informal consultation of experts: a protocol risk assessment at the field level, https://www.who. int/publications/i/item/WHO-HSE-PED-CED-2014-2; 2014 [accessed 15 January 2014].
- [10] World Health Organization. Eliminate yellow fever epidemics (EYE) strategy 2017–2026, https://www.who.int/publications/i/item/9789241513661; 2018 [accessed 21 January 2018].
- [11] Abreu FVS, de Andreazzi CS, Neves MSAS, Meneguete PS, Ribeiro MS, Dias CMG, et al. Ecological and environmental factors affecting transmission of sylvatic yellow fever in the 2017–2019 outbreak in the Atlantic Forest. *Brazil. Parasit Vectors* 2022;**15**:23. doi:10.1186/s13071-021-05143-0.
- [12] Ministry of Health. Yellow fever entry requirement in Tanzania mainland, https://www.moh.go.tz/storage/app/uploads/public/65a/f76/a77/65af76a77 7832906196271.pdf; 2023 [accessed 16 November 2023].
- [13] NBS Administrative units, population distribution report; 2022. Tanzania mainland:33 &173, https://www.nbs.go.tz/nbs/takwimu/Census2022/ Administrative\_units\_Population\_Distribution\_Report\_Tanzania\_Mainland\_ volume1b.pdf(accessed 22 December 2022).
- [14] Sadiq IZ, Usman A, Muhammad A, Ahmad KH. Sample size calculation in biomedical, clinical and biological sciences research. JUmm Al-Qura Univ Appll Sci 2024. doi:10.1007/s43994-024-00153-x.
- [15] NBS The United Republic of Tanzania (URT), Ministry of Finance and planning, Tanzania National Bureau of Statistics and president's office - finance and planning. Zanzibar: Office of the Chief Government Statistician; 2022. The 2022 Population and Housing Census: Administrative Units Population Distribution Report. Tanzania, https://sensa.nbs.go.tz/publication/volume1c.pdf; [accessed 30 December 2022].
- [16] Rugarabamu S, Mwanyika GO, Rumisha SF, Sindato C, Lim H-Y, Misinzo G, et al. Seroprevalence and associated risk factors of selected zoonotic viral hemorrhagic fevers in Tanzania. *Int J Infect Dis* 2021;**109**:174–81. doi:10.1016/j.ijid. 2021.07.006.
- [17] Ngingo BL, Mboera LEG, Chengula A, Machelle I, Makange MR, Msolla M, et al. Aedes aegypti abundance, larval indices and risk for dengue virus transmission in Kinondoni district. *Tanzania. Trop Med Health* 2022;**50**:1. doi:10.1186/ s41182-021-00395-z.
- [18] Manrique-Saide P. Operational guide for assessing the productivity of Aedes aegypti breeding sites. World Health Organization; 2011. https://tdr.who. int/publications/m/item/2011-10-31-operational-guide-for-assessing-theproductivity-of-aedes-aegypti-breeding-sites; [accessed 31 October 2011].
- [19] Ole Kwallah A, Inoue S, Thairu-Muigai AW, Kuttoh N, Morita K, Mwau M. Seroprevalence of yellow fever virus in selected health facilities in Western Kenya from 2010 to 2012. *Jpn J Infect Dis* 2015;**68**:230–4. doi:10.7883/yoken.JJID.2014. 288.
- [20] Gianchecchi E, Cianchi V, Torelli A, Montomoli E. Yellow fever: origin, epidemiology, preventive strategies and future prospects. *Vaccines* 2022;10:372. doi:10.3390/vaccines10030372.
- [21] Mengesha Tsegaye M, Beyene B, Ayele W, Abebe A, Tareke I, Sall A, et al. Sero-prevalence of yellow fever and related Flavi viruses in Ethiopia: a public health perspective. *BMC Public Health* 2018;**18**:1011. doi:10.1186/s12889-018-5726-9.
- [22] Muenchhoff M, Goulder PJR. Sex differences in pediatric infectious diseases. J Infect Dis 2014;209:S120-6. doi:10.1093/infdis/jiu232.
- [23] Wilder-Smith A, Leong WY. Importation of yellow fever into China: assessing travel patterns. J Travel Med 2017;24 tax008. doi:10.1093/jtm/tax008.
- [24] Otshudiema JO, Ndakala NG, Mawanda EK, Tshapenda GP, Kimfuta JM, Nsibu LRN, et al. Yellow fever outbreak - Kongo Central Province, Democratic Republic of the Congo, August 2016. MMWR Morb Mortal Wkly Rep 2017;66:335-8. doi:10.15585/mmwr.mm6612a5.
- [25] Abong'o B, Gimnig JE, Omoke D, Ochomo E, Walker ED. Screening eaves of houses reduces indoor mosquito density in rural, western Kenya. *Malar J* 2022;21:377. doi:10.1186/s12936-022-04397-y.
- [26] Kuno G. Mechanisms of yellow fever transmission: gleaning the overlooked records of importance and identifying problems, puzzles, serious issues, surprises and research questions. *Viruses* 2024;**16**:84. doi:10.3390/v16010084.
- [27] Rugarabamu S, Rumisha SF, Mwanyika GO, Sindato C, Lim H-Y, Misinzo G, et al. Viral haemorrhagic fevers and malaria co-infections among febrile patients seeking health care in Tanzania. *Infect Dis Poverty* 2022;**11**:33. doi:10. 1186/s40249-022-00959-z.
- [28] Kishimba R, Mghamba J, Mohamed M, Subi L. Is Tanzania prepared to respond and prevent Ebola outbreak. *Tanzan Public Health Bull* 2019;1:14.
- [29] Vanderslott S, Marks T. Health diplomacy across borders: the case of yellow fever and COVID-19. J Travel Med 2020;27:taaa112. doi:10.1093/jtm/taaa112.